» Articles » PMID: 17312278

Portal Vein Embolization and Autologous CD133+ Bone Marrow Stem Cells for Liver Regeneration: Initial Experience

Overview
Journal Radiology
Specialty Radiology
Date 2007 Feb 22
PMID 17312278
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To prospectively evaluate the effectiveness of portal vein embolization (PVE) and CD133(+) bone marrow stem cell (BMSC) administration to the liver, compared with PVE alone, to augment hepatic regeneration in patients with large hepatic malignancies.

Materials And Methods: The study was approved by the institutional ethics committee; informed consent was obtained. Thirteen patients underwent PVE of liver segments I and IV-VIII to stimulate hepatic regeneration prior to extended right hepatectomy. In six patients (three men, three women; mean age, 61 years; range, 46-72 years) with a future liver remnant volume (FLRV) below 25% and/or limited quality of hepatic parenchyma, PVE alone did not promise adequate proliferation. These patients underwent BMSC administration to segments II and III (group I). In seven patients (three men, four women; mean age, 69 years; range, 63-75 years) with an FLRV below 25%, PVE alone was performed (group II). Two radiologists blinded to patients' identity and each other's results measured liver and tumor volumes with helical computed tomography. Absolute, relative, and daily FLRV gains were compared by using the t test or the Wilcoxon test.

Results: The increase of the mean absolute FLRV in group I from 239.3 mL +/- 103.5 (standard deviation) to 417.1 mL +/- 150.4 was significantly higher than that from 286.3 mL +/- 77.1 to 395.9 mL +/- 94.1 in group II (P = .049). The relative gain of FLRV after PVE in group I (77.3% +/- 38.2) was significantly higher than that in group II (39.1% +/- 20.4) (P = .039). The daily hepatic growth rate in group I (9.5 mL/d +/- 4.3) was significantly superior to that in group II (4.1 mL/d +/- 1.9) (P = .03). Time to surgery was 27 days +/- 11 in group I and 45 days +/- 21 in group II (P = .057).

Conclusion: In patients with malignant liver lesions, the combination of PVE with CD133(+) BMSC administration substantially increased hepatic regeneration compared with PVE alone.

Citing Articles

Liver Regeneration Following Thermal Ablation Using Nanocarrier Mediated Targeted Mesenchymal Stem Cell Therapy.

Mohan P, Deo S, Liu Z, Dikici E, Kaneku H, Chang D Cardiovasc Intervent Radiol. 2024; 48(2):233-243.

PMID: 39505737 PMC: 11790787. DOI: 10.1007/s00270-024-03862-2.


Comprehensive Review of Future Liver Remnant (FLR) Assessment and Hypertrophy Techniques Before Major Hepatectomy: How to Assess and Manage the FLR.

Boubaddi M, Marichez A, Adam J, Lapuyade B, Debordeaux F, Tlili G Ann Surg Oncol. 2024; 31(13):9205-9220.

PMID: 39230854 DOI: 10.1245/s10434-024-16108-9.


Current Perspectives and Progress in Preoperative Portal Vein Embolization with Stem Cell Augmentation (PVESA).

Barcena A, Owens T, Melancon S, Workeneh I, Tran Cao H, Vauthey J Stem Cell Rev Rep. 2024; 20(5):1236-1251.

PMID: 38613627 PMC: 11222268. DOI: 10.1007/s12015-024-10719-1.


Portal Vein Embolization: Rationale, Techniques, and Outcomes to Maximize Remnant Liver Hypertrophy with a Focus on Contemporary Strategies.

Charles J, Nezami N, Loya M, Shube S, Davis C, Hoots G Life (Basel). 2023; 13(2).

PMID: 36836638 PMC: 9959051. DOI: 10.3390/life13020279.


Portal vein embolization failure: Current strategies and future perspectives to improve liver hypertrophy before major oncological liver resection.

Cassese G, Han H, Lee B, Cho J, Lee H, Guiu B World J Gastrointest Oncol. 2022; 14(11):2088-2096.

PMID: 36438704 PMC: 9694272. DOI: 10.4251/wjgo.v14.i11.2088.